このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

KALA BIO 配当金

配当金基準チェック /06

KALA BIO配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	2.8%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$14.04
3年後の配当利回り予想	n/a

最近の配当金アップデート

更新なし

Recent updates

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Aug 10

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Jul 07

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Apr 05

Kala Pharmaceuticals, Inc. (NASDAQ:KALA): When Will It Breakeven?

Mar 08

What Kind Of Investors Own Most Of Kala Pharmaceuticals, Inc. (NASDAQ:KALA)?

Feb 15

How Many Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Shares Did Insiders Buy, In The Last Year?

Jan 25

If You Had Bought Kala Pharmaceuticals (NASDAQ:KALA) Stock A Year Ago, You Could Pocket A 77% Gain Today

Jan 04

Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved

Dec 23

The Play On Kala Pharmaceuticals

Dec 17

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Too Much Debt?

Dec 14

How Much Did Kala Pharmaceuticals' (NASDAQ:KALA) CEO Pocket Last Year?

Nov 26

決済の安定と成長

配当データの取得

安定した配当: KALAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: KALAの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

KALA BIO 配当利回り対市場

KALA 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (KALA)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.8%
業界平均 (Biotechs)	2.8%
3年後のアナリスト予想 (KALA)	n/a

注目すべき配当: KALAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: KALAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: KALAの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: KALAが配当金を報告していないため、配当金の持続可能性を計算できません。

KALA BIO 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New minor risk - Share price stability

Price target decreased by 13% to US$26.00

Price target decreased by 9.7% to US$31.00

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Price target decreased to US$42.00

Price target decreased to US$90.67

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Kala Pharmaceuticals to execute reverse stock split

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kala Pharmaceuticals Q2 2022 Earnings Preview

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Consensus revenue estimates fall by 27%

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$4.55

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

Staying Patient With Kala Pharmaceuticals

Consensus revenue estimates fall to US$19.9m

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Price target decreased to US$16.50

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Consensus forecasts updated

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

Kala Pharmaceuticals, Inc. (NASDAQ:KALA): When Will It Breakeven?

Chief Scientific Officer exercised options to buy US$346k worth of stock.

Full year 2020 earnings released: US$1.99 loss per share (vs US$2.76 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Analysts lower revenue estimates to US$32.0m

Kala Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

What Kind Of Investors Own Most Of Kala Pharmaceuticals, Inc. (NASDAQ:KALA)?

New 90-day high: US$8.21

How Many Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Shares Did Insiders Buy, In The Last Year?

Kala Pharmaceuticals, Inc. Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

If You Had Bought Kala Pharmaceuticals (NASDAQ:KALA) Stock A Year Ago, You Could Pocket A 77% Gain Today

Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved

The Play On Kala Pharmaceuticals

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Too Much Debt?

How Much Did Kala Pharmaceuticals' (NASDAQ:KALA) CEO Pocket Last Year?

Kala Pharmaceuticals, Inc. Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease

Analysts lower revenue estimates to US$6.66m

Revenue and earnings beat expectations

Third quarter 2020 earnings released: US$0.50 loss per share

配当金基準チェック /06